Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Molecular Partners AGNASDAQ: MOLN

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of CHF 298.51K (cash outflow) fell 1.2% year over year, ahead of the -109.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 19.8% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -1.2% holds above the trailing-twelve-month pace of -109.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 298.51K-19.8% QoQ
Last fiscal yearDec 2025
-CHF 1.15M-108.0% YoY
LTMMar 2026
-CHF 1.3M-109.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.2%——
1 year-108.0%——
3-year CAGR-9.9%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

CHF · from the cash flow

Latest · FY2025
(1.15M) CHF
Year-over-year change
-108.0%

Financing Cash Flow vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -109.0% is the lowest of 9, against a peer median of +137.4%.
  • Over three fiscal years its annual growth of -9.9% compares with a peer median of +20.1%.
MOLN Competitors
Financing Cash Flow for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$180.48M USD+300903.0%+202.6%10116.9%
PEPGPepGen Inc.LTM Mar 2026$109.5M USD+6044.6%-1.3%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$77.43M USD+29.1%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$44M USD+352.1%+11.6%1388.6%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$34.39M USD-17.4%+20.1%—
ALECAlector, Inc.LTM Mar 2026$20.24M USD+94.0%+64.8%109.9%
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.68M USD-95.0%+225.3%511.0%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.3M CHF-109.0%-9.9%—
NKTXNkarta, Inc.LTM Mar 2026$147K USD+180.8%-91.4%—
Peer median (excluding MOLN) —+137.4%+20.1%949.8%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
Deferred Income Tax2K002K2K
Stock-Based Compensation4.09M5.09M5.21M4.11M4.42M
Change in Working Capital(34.67M)(6.01M)(6.01M)(3.8M)1.16M
Accounts Receivables(23.37M)25.26M(933K)(347K)463.2K
Inventory21.72M(19.93M)000
Accounts Payables1.66M(5.34M)(812K)524K62.08K
Other Working Capital(34.67M)(6.01M)(4.27M)(3.97M)630.33K
Other Non-Cash Items848K(753K)1.36M(7.88M)2.67M
Operating Cash Flow(90.95M)118.57M(59.01M)(59.25M)(51.26M)
Capital Expenditures(1.31M)(1.42M)(575K)(723K)(714K)
Acquisitions (Net)374K0000
Purchases of Investments(88.88M)(299.42M)(277.83M)(240.05M)(66.28M)
Sales of Investments67.88M199.22M319.44M277.02M137.81M
Other Investing Activities(304K)494K3.83M4.22M1.73M
Investing Cash Flow(22.24M)(101.12M)44.64M40.49M72.55M
Debt Repayment(1.18M)(1.19M)(1.2M)(1.21M)(1.21M)
Common Stock Issued51.49M250K31K17.34M63K
Common Stock Repurchased0(631K)000
Dividends Paid00000
Other Financing Activities267K250K31K(1.7M)0
Financing Cash Flow50.58M(1.57M)(1.17M)14.43M(1.15M)
Effect of Forex Changes701K258K(5.1M)894K(1.36M)
Net Change in Cash(61.91M)16.13M(20.64M)(3.44M)18.78M
Free Cash Flow(92.26M)117.15M(59.81M)(59.97M)(51.97M)

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.